Table. 5.

Table. 5.

Other diseases: characteristics of selected clinical trials included in the review

Reference Type of study Clinical setting/population Sample size Age (year) Daily dose Probiotic species Duration of intervention System Main outcomes
Di Pierro et al., 2020 (Italy) Non-randomized clinical trial Non-celiac gluten sensitivity 30 Int: 46.87±17.06 Plac: 43.53±18.94 1 dose/day 1×109 CFU (1 billion) Bifidobacterium longum ES1 or GFD 3 months Document of scientific support to the protocol for the diagnosis and follow-up of celiac disease Positive effect
Chen et al., 2016 (Taiwan) RCT Gastric bypass surgery 53 18-60 35.1±8.3 Twice daily A: 5×109 CFU (5 billion) B: 8×109 CFU (8 billion) A: 1 g Clostridium butyricum MIYAIRI B: 300 mg Bifidobacterium longum BB536 2 weeks mGIQL Positive effect
Fujimori et al., 2009 (Japan) RCT Ulcerative colitis 83 Pro=36±16 Pre=37±13 Syn=35±10 2×109 CFU Bifidobacterium longum Also prebiotic (psyllium) and synbiotic 4 weeks IBDQ Positive effect

RCT, randomized control trial; Int, intervention; Plac, placebo; Pro, probiotics; Pre, prebiotics; Syn, symbiotic; CFU, colony forming unit; GFD, gluten-free diet; mGIQL, modified Gastrointestinal QoL Index; IBDQ, Inflammatory Bowel Disease Questionnaire.
Prev Nutr Food Sci 2024;29:237~255 https://doi.org/10.3746/pnf.2024.29.3.237
© Prev. Nutr. Food Sci.
Copyright © 2020 by Preventive Nutrition and Food Science. All right reserved.